Hudson Bay Capital Management
OREX

Hudson Bay Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Hudson Bay Capital Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-10,000
Closed -$563K – 228
2013
Q4 		$563K Hold
10,000
– – 0.02% 138
2013
Q3 		$614K Buy
+10,000
New +$677K 0.02% 153

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Hudson Bay Capital Management's OREX Position: Q3 2014 in Review

Hudson Bay Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2014, closing a stake of 92,266 shares — an estimated $5.7M sold.

Hudson Bay Capital Management first reported a position in OREX in Q2 2013 and held it in 5 quarters. The position peaked at $6.16M in Q1 2014. 128 funds tracked by Wall St. Rank hold OREX as of Q3 2014.

  • Hudson Bay Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • Hudson Bay Capital Management sold 92,266 Orexigen Therapeutics, Inc. shares in Q3 2014, an estimated $5.7M.
  • Hudson Bay Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 5 quarters.
  • Hudson Bay Capital Management's Orexigen Therapeutics, Inc. position peaked at $6.16M in Q1 2014.
  • 128 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2014.

Based on Hudson Bay Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.